Skip to main content

Systemic Corticosteroid Use for COVID-19 in US Outpatient Settings From April 2020 to August 2021

    Basic Details

    In June 2020, preliminary results for the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial conducted in the UK indicated benefit from dexamethasone in severely ill hospitalized patients with COVID-19 but potential harm in those not requiring oxygen. In October 2020, the National Institutes of Health (NIH) issued COVID-19 treatment guidelines advising against systemic corticosteroid use in patients with mild to moderate COVID-19. Using two large US health care claims databases, we examined systemic corticosteroid use among non-hospitalized patients with COVID-19.


    Marie C. Bradley, Silvia Perez-Vilar, Yoganand Chillarige, Diane Dong, Ashley I. Martinez, Andrew R. Weckstein, Gerald J. Dal Pan

    Corresponding Author

    Marie C. Bradley; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration